Scinai Immunotherapeutics (SCNI) Gains from Investment Securities (2019 - 2025)

Scinai Immunotherapeutics has disclosed Gains from Investment Securities across 7 years of filings, most recently posting $510.4 million for Q4 2025.

• Gains from Investment Securities for Q4 2025 came in at $510.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $510.4 million (up 548947.74% YoY), and the FY2025 annual result was $510.4 million, up 424.98% from the prior year.
• Gains from Investment Securities came in at $510.4 million for Q4 2025 at Scinai Immunotherapeutics, up from $3000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $510.4 million in Q4 2025 to a low of -$2.6 million in Q1 2023.
• The 5-year median for Gains from Investment Securities is -$1000.0 (2021), against an average of $41.2 million.
• Across the five-year window, Gains from Investment Securities surged 11899.83% in 2022 and slumped 814.95% in 2023, its largest moves.
• Scinai Immunotherapeutics' Gains from Investment Securities stood at $241000.0 in 2021, then soared by 11899.83% to $28.9 million in 2022, then tumbled by 100.75% to -$216000.0 in 2023, then jumped by 101.39% to $3000.0 in 2024, then soared by 17014180.0% to $510.4 million in 2025.
• The last three Gains from Investment Securities figures came in at $510.4 million (Q4 2025), $3000.0 (Q2 2024), and -$96000.0 (Q1 2024), per Business Quant data.